|
WO2018165266A1
|
|
Compositions and methods for treating dry eye diseases
|
|
US2019038653A1
|
|
Compounds and methods for treating inflammatory diseases
|
|
AU2018220172A1
|
|
Triazole-containing macrolides and ophthalmic uses therefor
|
|
TW201811811A
|
|
Processes for preparing fluoroketolides
|
|
HK1221229A1
|
|
Crystalline forms of a macrolide, and uses therefor
|
|
US2018044365A1
|
|
Processes for preparing fluoroketolides
|
|
US2018016226A1
|
|
4-azidobutylamines and processes for preparing
|
|
IL241670A
|
|
Convergent processes for preparing macrolide antibacterial agents
|
|
CN106604729A
|
|
Powder oral suspension formulations of antibacterial agents
|
|
KR20160113307A
|
|
Compositions and methods for treating diabetes and liver diseases
|
|
CA2907085A1
|
|
Convergent processes for preparing macrolide antibacterial agents
|
|
EP2968801A1
|
|
Methods for treating respiratory diseases and formulations therefor
|
|
EP2830632A1
|
|
Parenteral formulations for administering macrolide antibiotics
|
|
KR20180110181A
|
|
Hydrogen bond forming fluoro ketolides for treating diseases
|
|
CA2812044A1
|
|
Methods of treating bacterial infections through pulmonary delivery of fusidic acid
|
|
KR20130120374A
|
|
Processes for preparing macrolides and ketolides and intermediates therefor
|
|
CN103080122A
|
|
Crystalline forms of a macrolide, and uses therefor
|
|
CN109091489A
|
|
The parenteral administration of macrolide antibiotics
|
|
WO2011032052A1
|
|
Methods for treating malaria, tuberculosis and mac diseases
|
|
AU2009308180A1
|
|
Methods for treating gastrointestinal diseases
|
